Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;41(1):52-9.
doi: 10.1007/s12029-009-9110-y. Epub 2009 Dec 4.

Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas

Affiliations

Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas

Erika Rendón-Huerta et al. J Gastrointest Cancer. 2010 Mar.

Abstract

Introduction: Intestinal- and diffuse-type gastric adenocarcinomas differ in clinical outcome and genetic profile. Abnormal claudin expression has been well documented in several malignancies. Our aim was to find specific claudin markers for each type.

Methods: Fifty paraffin-embedded tissue blocks of diffuse- and intestinal-type gastric adenocarcinomas and fresh gastric biopsies obtained endoscopically from 20 patients with a presumptive diagnosis of gastric cancer were analyzed. Claudin-specific polyclonal and monoclonal antibodies were used for immunohistochemistry and Western blot analysis in total lysate and subcellular fractions.

Results: Claudin-6 expression was high in both types. Claudin-7 was expressed mainly in the diffuse-type whereas claudin-9 was mainly found in the apical membrane of the gland cells in the intestinal-type. Strong claudin-9 expression was associated with higher mortality rate (66%) in the diffuse type vs the intestinal type (25%) after a 2-year follow-up.

Conclusion: Claudins 6, 7, and 9 expressions are closely related to gastric carcinogenesis, and their detection is a useful prognostic marker in "intestinal-" and "diffuse-type" gastric adenocarcinomas.

PubMed Disclaimer

References

    1. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):511-6 - PubMed
    1. Clin Immunol. 2008 Jan;126(1):67-80 - PubMed
    1. Curr Opin Crit Care. 2003 Apr;9(2):143-51 - PubMed
    1. Infect Immun. 2005 Dec;73(12):7844-52 - PubMed
    1. Clin Cancer Res. 2008 May 15;14(10):3022-9 - PubMed

Publication types

LinkOut - more resources